A Cross-sectional Study to Measure Cough in Severe Asthma
NCT ID: NCT03999203
Last Updated: 2023-11-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
61 participants
INTERVENTIONAL
2017-10-04
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
60 patients are expected to be recruited to the study. Patients will be provided with an information sheet and have a telephone follow-up after at least 24 hours to ask if they remain interested in participation and if so, they will then be asked back for a baseline visit.
Three groups of severe asthmatics will be recruited (as described in appropriate section) and undergo the following procedures:
* Demographic details, height, weight, spirometry, FeNO and vital signs
* Patient reported outcomes:
* Asthma Mini-Asthma Quality of Life Questionnaire (mini-AQLQ) - abbreviated version of Juniper AQLQ
* Asthma Control Questionnaire (ACQ-5 (5 questions);
* Leicester Cough Questionnaire, the Cough-specific quality-of-life Questionnaire and Cough Hypersensitivity Questionnaire will be used to assess the impact of cough;
* Visual analogue scales (VAS) for cough (VASc) and urge to cough (VASu) will be used as a measure of cough severity.
* Blood samples - a sample of blood will be taken for whole blood transcriptomic and serum analyses
* Citric acid cough challenge test will be used to measure cough reflex sensitivity in each phenotype.
* Spontaneous sputum sample - if patients produce a sputum sample during spirometry or citric acid challenge, this will be recorded and the sample will be retained for sputum differential cell count and storage of processed soluble components.
* On completing the above procedures, patients will be asked to wear a validated ambulatory cough monitor (Leicester Cough Monitor) for a 24-hour period to assess the frequency of cough and if they agree, will be fully instructed in its use.
Patients will be asked to attend a follow-up visit 2 weeks after baseline. The study procedures will remain the same as visit 1 with the exception of collection of clinical samples.
A mild/moderate population will be recruited and undergo the same procedures as the severe group in a baseline visit. No mild/moderate asthmatics will be asked to attend for a follow-up visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A - T2 High Severe Asthmatics
Severe asthmatic patients with eosinophil count ≥ 0.15x10\^9/mL andhigh FeNO levels ≥20 ppb.
Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
Citric acid
Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Leicester Cough monitor
Ambulatory cough monitor to assess cough frequency over a 24 hour period
fractional exhaled nitric oxide testing (FeNO)
Measurement of exhaled nitric oxide to give an indication of airway inflammation
Patient reported outcome measures
A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
B - T2 Low Severe Asthmatics
Severe asthmatic patients with eosinophil count ≤ 0.15x10\^9/mL and low FeNO levels \<20 ppb.
Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
Citric acid
Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Leicester Cough monitor
Ambulatory cough monitor to assess cough frequency over a 24 hour period
fractional exhaled nitric oxide testing (FeNO)
Measurement of exhaled nitric oxide to give an indication of airway inflammation
Patient reported outcome measures
A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
C - Mild/Moderate Asthmatics
mild/moderate severe asthmatics (defined as step 2/3 using the GINA classification of severity) recruited from general respiratory clinics in the Belfast HSC Trust Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
Citric acid
Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Leicester Cough monitor
Ambulatory cough monitor to assess cough frequency over a 24 hour period
fractional exhaled nitric oxide testing (FeNO)
Measurement of exhaled nitric oxide to give an indication of airway inflammation
Patient reported outcome measures
A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
D - T2 Intermediate
Severe asthmatic patients with eosinophil count ≥ 0.15x10\^9/mL OR high FeNO levels ≥20 ppb.
Interventions include 24 hour ambulatory cough monitoring (Leicester Cough Monitor), citric acid cough challenge, fractional exhaled nitric oxide (FeNO) testing, patient reported outcome measures and blood, urine and sputum sampling
Citric acid
Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Leicester Cough monitor
Ambulatory cough monitor to assess cough frequency over a 24 hour period
fractional exhaled nitric oxide testing (FeNO)
Measurement of exhaled nitric oxide to give an indication of airway inflammation
Patient reported outcome measures
A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Citric acid
Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Leicester Cough monitor
Ambulatory cough monitor to assess cough frequency over a 24 hour period
fractional exhaled nitric oxide testing (FeNO)
Measurement of exhaled nitric oxide to give an indication of airway inflammation
Patient reported outcome measures
A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 to ≤75 years at the time of informed consent
3. Severe asthma (as defined by GINA step 4/5 classification of asthma severity) after a detailed systematic assessment
4. History of asthma treatment with high doses of Inhaled Corticosteroids (≥1000 µg beclomethasone dipropionate daily, or equivalent) and an additional controller
5. Three patient groups with severe asthma will be investigated in the study and will be defined as follows:
T2-High Severe Asthmatics (Group A)
* Persistent blood eosinophil count ≥0.3x10\^9/mL and
* Persistent high FeNO levels ≥30 ppb and
* Adherence to inhaled and oral corticosteroid therapy
T2-Low Severe Asthmatics (Group B)
* Persistent blood eosinophil count ≤0.2x10\^9/Ml and
* Persistent low FeNO levels (\<30ppb)
T2 - Intermediate Severe Asthmatics (Group D)
* Persistent blood eosinophil count ≥ 0.3x10\^9/mL OR
* Persistent FeNO levels ≥ 30 ppb
As stated above, these measurements are made at each clinic visit as part of routine care and will be available on all subjects prior to Inclusion
6. A chest x-ray or CT scan obtained within 12 months before the time of informed consent and showing no new pathology requiring investigation as a potential cause for their cough
Mild/moderate severe asthmatics (who have received a diagnosis of asthma from a physician and are defined as step 2/3 using the BTS/SIGN classification of severity and ACQ\<1.5) aged 18-75 years inclusive will be recruited from general respiratory clinics in the Belfast HSC Trust. Patients must have the ability and willingness to comply with study procedures.
Exclusion Criteria
2. Asthma exacerbation within 28 days before the time of informed consent or during screening
3. Major episode of infection requiring any of the following:
* Admission to hospital for ≥24 hours within the 28 days before the time of informed consent
* Treatment with intravenous antibiotics within the 28 days before the time of informed consent or during Screening
* Treatment with oral antibiotics within the 14 days before the time of informed consent or during Screening
4. For adults: Active tuberculosis (TB) requiring treatment within the 12 months before the time of informed consent (patients are also required to have no recurrence of symptoms in the 12 months following completion of TB treatment), or
5. Known history of severe clinically significant immunodeficiency, including, but not limited to, human immunodeficiency virus infection and/or currently receiving or have historically received intravenous Ig for treatment for immunodeficiency Note: Immunodeficiency encompasses a wide spectrum of human conditions and/or diseases. A relative IgG deficiency that is thought, but not proven, to be a feature of severe asthma would not be exclusionary for the study.
6. Diagnosis or history of malignancy, or current investigation for possible malignancy
7. Other clinically significant medical disease that is uncontrolled despite treatment or that is likely, in the opinion of the investigator, to require a change in therapy or affect the ability to participate in the study
8. History of alcohol, drug, or chemical abuse that would impair or risk the patient's full participation in the study, in the opinion of the investigator
9. Current smoker or former smoker with a smoking history of \>15 pack-years A current smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥30 days within the 24 months before the time of informed consent and for whom cotinine testing is positive.
A former smoker is defined as someone who has smoked one or more cigarettes per day (or marijuana or pipe or cigar) for ≥30 days in his or her lifetime (as long as the 30-day total did not include the 24 months before the time of informed consent) and for whom cotinine testing is negative.
A pack-year is defined as the average number of packs per day times the number of years of smoking.
10. Initiation of or change in allergen immunotherapy within three months before the time of informed consent
11. Treatment with an investigational agent within 30 days of informed consent or 5 half-lives of the investigational agent, whichever is longer
12. Female patients who are pregnant or lactating
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King's College London
OTHER
Queen's University, Belfast
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liam Heaney
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liam Heaney, MD
Role: PRINCIPAL_INVESTIGATOR
Queen's University, Belfast
Lorcan McGarvey, MD
Role: STUDY_CHAIR
Queen's University, Belfast
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen's University Belfast
Belfast, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B17/03
Identifier Type: -
Identifier Source: org_study_id